Sector News

Horizon hikes Depomed offer to $2B in bid for ‘friendly’ deal talks

July 21, 2015
Life sciences
Don’t get Horizon Pharma wrong. It intends to pursue Depomed as an M&A target whether the California company likes it or not. But it would prefer for Depomed to like it–and in an effort to spur a “friendly, negotiated transaction,” it’s raising its bid.
 
Tuesday, the Irish pharma put forth a $33 per share proposal–up from its previous $29.25-per-share offer. The new bid represents a 60% premium to Depomed’s share price the day before Horizon took its intentions public, or about $1.97 billion. But that price is contingent on Depomed “rapidly entering into good faith discussions regarding a transaction,” Horizon CEO Timothy Walbert wrote in a letter to his target’s board.
 
On that front, Walbert said his company remains “surprised and disappointed” that Depomed hasn’t yet come to the bargaining table. Based on talks Horizon has had with shareholders on both sides, “it is clear that they and the investment community strongly support a combination of our two businesses,” he said in a statement.
 
For its part, Depomed so far hasn’t shown any signs that it’s up for a buyout. Last week, it adopted a poison pill plan that would be triggered if any person or group picks up an ownership stake larger than 10%.
 
But Depomed’s reticence won’t stop Horizon from moving forward, Walbert stressed: “Horizon remains committed to an acquisition of Depomed and we are prepared to consider all paths necessary to complete the transaction,” he said.
 
By Carly Helfand
 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach